Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Cancer Research Communications|September 3, 2025
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumorsJohn Powderly, Martina Imbimbo, Antoine Italiano, et al.
Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Cancer Research|October 10, 2014
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanomaY N Vashisht Gopal, Helen Rizos, Guo Chen, et al.
EMBO Molecular Medicine|June 14, 2017
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failureMichael P Smith, Emily J Rowling, Zsofia Miskolczi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2012
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanomaJahan S Khalili, Shujuan Liu, Tania G Rodríguez-Cruz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2012
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in miceChengwen Liu, Weiyi Peng, Chunyu Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2013
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanomaDennie T Frederick, Adriano Piris, Alexandria P Cogdill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2016
Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell CarcinomaLaurence Feldmeyer, Courtney W Hudgens, Genevieve Ray-Lyons, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 6, 2024
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaAndrew L Coveler, Matthew J Reilley, Mark Zalupski, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2023
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumorsJohanna Bendell, Patricia LoRusso, Michael Overman, et al.
Pageof 9